HUTCHMED (China) Limited (HCM)
USD 15.68
(12.89%)
USD 15.68
(12.89%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 100.78 Million USD | 124.57% |
| 2022 | -410.13 Million USD | -80.16% |
| 2021 | -227.65 Million USD | -17.01% |
| 2020 | -194.56 Million USD | -34.76% |
| 2019 | -144.37 Million USD | -93.01% |
| 2018 | -74.8 Million USD | -179.78% |
| 2017 | -26.73 Million USD | -328.56% |
| 2016 | 11.69 Million USD | 46.35% |
| 2015 | 7.99 Million USD | 48.73% |
| 2014 | 5.37 Million USD | -9.15% |
| 2013 | 5.91 Million USD | 62.59% |
| 2012 | 3.63 Million USD | 412.23% |
| 2011 | 710.22 Thousand USD | 110.35% |
| 2010 | -6.86 Million USD | 21.55% |
| 2009 | -8.74 Million USD | 50.72% |
| 2008 | -17.75 Million USD | -3.29% |
| 2007 | -17.18 Million USD | -78.94% |
| 2006 | -9.6 Million USD | -41.77% |
| 2005 | -6.77 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 12.9 Million USD | 138.07% |
| 2024 Q2 | 12.9 Million USD | 0.0% |
| 2023 Q2 | 84.27 Million USD | 0.0% |
| 2023 Q4 | -33.88 Million USD | 0.0% |
| 2023 FY | 100.78 Million USD | 124.57% |
| 2023 Q1 | 84.27 Million USD | 185.14% |
| 2023 Q3 | -33.88 Million USD | -140.21% |
| 2022 FY | -410.13 Million USD | -80.16% |
| 2022 Q4 | -98.98 Million USD | 0.0% |
| 2022 Q3 | -98.98 Million USD | 39.22% |
| 2022 Q2 | -162.86 Million USD | -100.0% |
| 2022 Q1 | -81.43 Million USD | -205.83% |
| 2021 Q4 | -26.62 Million USD | 42.27% |
| 2021 FY | -227.65 Million USD | -17.01% |
| 2021 Q3 | -46.12 Million USD | 40.45% |
| 2021 Q1 | -64.84 Million USD | -70.57% |
| 2021 Q2 | -77.46 Million USD | -19.45% |
| 2020 Q4 | -38.01 Million USD | 0.0% |
| 2020 FY | -194.56 Million USD | -34.76% |
| 2020 Q2 | -33.55 Million USD | -107.87% |
| 2020 Q1 | -16.14 Million USD | 56.78% |
| 2020 Q3 | -38.01 Million USD | -13.31% |
| 2019 Q1 | -19.88 Million USD | 54.46% |
| 2019 Q2 | -25.48 Million USD | -28.16% |
| 2019 FY | -144.37 Million USD | -93.01% |
| 2019 Q3 | -31.09 Million USD | -22.01% |
| 2019 Q4 | -37.34 Million USD | -20.12% |
| 2018 Q3 | -25.57 Million USD | -22.03% |
| 2018 Q2 | -20.96 Million USD | -78.7% |
| 2018 Q1 | -11.73 Million USD | 58.01% |
| 2018 FY | -74.8 Million USD | -179.78% |
| 2018 Q4 | -43.66 Million USD | -70.73% |
| 2017 FY | -26.73 Million USD | -328.56% |
| 2017 Q3 | -14.2 Million USD | -944.8% |
| 2017 Q4 | -27.93 Million USD | -96.58% |
| 2017 Q1 | 841 Thousand USD | -84.93% |
| 2017 Q2 | 1.68 Million USD | 100.0% |
| 2016 Q1 | 268.5 Thousand USD | -92.01% |
| 2016 FY | 11.69 Million USD | 46.35% |
| 2016 Q2 | 268.5 Thousand USD | 0.0% |
| 2016 Q4 | 5.58 Million USD | 0.0% |
| 2016 Q3 | 5.58 Million USD | 1978.4% |
| 2015 Q3 | 2.33 Million USD | 117.93% |
| 2015 FY | 7.99 Million USD | 48.73% |
| 2015 Q4 | 3.35 Million USD | 43.73% |
| 2015 Q2 | -13.03 Million USD | 0.0% |
| 2015 Q1 | -13.03 Million USD | -232.79% |
| 2014 FY | 5.37 Million USD | -9.15% |
| 2014 Q4 | 9.81 Million USD | 190.14% |
| 2014 Q2 | 2.34 Million USD | 0.0% |
| 2014 Q1 | 2.34 Million USD | -87.86% |
| 2014 Q3 | -10.88 Million USD | -563.56% |
| 2013 Q3 | 1.31 Million USD | -49.83% |
| 2013 Q1 | 2.62 Million USD | -31.54% |
| 2013 Q2 | 2.62 Million USD | 0.0% |
| 2013 FY | 5.91 Million USD | 62.59% |
| 2013 Q4 | 19.34 Million USD | 1367.24% |
| 2012 FY | 3.63 Million USD | 412.23% |
| 2012 Q3 | 3.83 Million USD | 0.0% |
| 2012 Q4 | 3.83 Million USD | 0.0% |
| 2011 FY | 710.22 Thousand USD | 110.35% |
| 2010 FY | -6.86 Million USD | 21.55% |
| 2009 FY | -8.74 Million USD | 50.72% |
| 2008 FY | -17.75 Million USD | -3.29% |
| 2007 FY | -17.18 Million USD | -78.94% |
| 2006 FY | -9.6 Million USD | -41.77% |
| 2005 FY | -6.77 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alvotech | -551.73 Million USD | 118.266% |
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | -109.283% |
| Journey Medical Corporation | -3.85 Million USD | 2715.624% |
| Dynavax Technologies Corporation | -6.38 Million USD | 1677.399% |
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | 172.154% |
| PainReform Ltd. | -9.34 Million USD | 1178.553% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | 2336.552% |
| SCYNEXIS, Inc. | 67.04 Million USD | -50.326% |
| Silver Spike Investment Corp. | 7.34 Million USD | -1273.004% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | 2336.552% |
| Bright Green Corporation | -13.12 Million USD | 867.693% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 148.163% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | 1380.559% |
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | -436.663% |
| Alpha Teknova, Inc. | -36.78 Million USD | 374.008% |
| Embecta Corp. | 70.4 Million USD | -43.153% |
| Safety Shot Inc | -15.08 Million USD | 768.168% |
| Procaps Group, S.A. | 42.54 Million USD | -136.906% |
| Cosmos Health Inc. | -18.54 Million USD | 643.504% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | 3352.508% |
| Pacira BioSciences, Inc. | 41.95 Million USD | -140.21% |
| Theratechnologies Inc. | -23.95 Million USD | 520.67% |
| Harrow Health, Inc. | -24.41 Million USD | 512.847% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | 2184.385% |
| Biofrontera Inc. | -20.13 Million USD | 600.621% |
| DURECT Corporation | -27.62 Million USD | 464.828% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | -7558.055% |
| Cronos Group Inc. | -73.96 Million USD | 236.257% |
| OptiNose, Inc. | -35.48 Million USD | 384.023% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 110.055% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 338.821% |
| RedHill Biopharma Ltd. | 23.91 Million USD | -321.392% |
| Organogenesis Holdings Inc. | 4.94 Million USD | -1938.018% |
| Guardion Health Sciences, Inc. | 158.03 Thousand USD | -63671.491% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | 1704.951% |
| Radius Health, Inc. | -25.79 Million USD | 490.756% |
| Universe Pharmaceuticals INC | -6.16 Million USD | 1735.226% |
| ProPhase Labs, Inc. | -16.78 Million USD | 700.524% |
| Phibro Animal Health Corporation | 2.41 Million USD | -4071.358% |
| Procaps Group S.A. | 42.54 Million USD | -136.906% |
| TherapeuticsMD, Inc. | -10.27 Million USD | 1080.541% |
| Viatris Inc. | 54.7 Million USD | -84.241% |
| Rockwell Medical, Inc. | -8.43 Million USD | 1294.217% |
| Aytu BioPharma, Inc. | -15.84 Million USD | 736.077% |
| SIGA Technologies, Inc. | 68.06 Million USD | -48.056% |
| Tilray Brands, Inc. | -244.98 Million USD | 141.138% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | -738.924% |
| Shineco, Inc. | -22.44 Million USD | 548.928% |
| PetIQ, Inc. | 2.13 Million USD | -4629.235% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | 2442.72% |
| Incannex Healthcare Limited | -18.45 Million USD | 645.967% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 59.64% |
| Alimera Sciences, Inc. | -20.13 Million USD | 600.596% |
| Assertio Holdings, Inc. | -331.94 Million USD | 130.361% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | 1628.655% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | 1334.567% |
| Clever Leaves Holdings Inc. | -17.89 Million USD | 663.048% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 602.46% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | 162.879% |
| Hempacco Co., Inc. | -13.12 Million USD | 867.784% |
| Talphera, Inc. | -18.39 Million USD | 647.807% |
| Alvotech | -551.73 Million USD | 118.266% |
| Eagle Pharmaceuticals, Inc. | 35.64 Million USD | -182.756% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 69.148% |
| Currenc Group, Inc. | -15.3 Million USD | 758.411% |
| Kamada Ltd. | 8.28 Million USD | -1116.562% |
| Indivior PLC | 2 Million USD | -4939.0% |
| Evoke Pharma, Inc. | -7.79 Million USD | 1393.329% |
| Flora Growth Corp. | -57.03 Million USD | 276.695% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 602.46% |
| Evolus, Inc. | -61.68 Million USD | 263.378% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 26.729% |
| Akanda Corp. | -32.27 Million USD | 412.253% |